Blistering rash in a patient with psoriasis
Article Sidebar
Main Article Content
Abstract
.
Downloads
Article Details
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
How to Cite
References
Yancey KB, Egan CA. Pemphigoid: clinical,histologic, immunopathologic, and therapeuticconsiderations. JAMA 2000;284(3):350-6.
Mutasim DF, Bilic M, Hawayek LH, et al.Immunobullous diseases. J Am Acad Dermatol2005;52(6):1029-43.
McKenna JK, Leiferman KM. Dermatologicdrug reactions. Immunol Allergy Clin North Am2004;24(3):399-423, vi.
Smith EP, Taylor TB, Meyer LJ, et al. Antigenidentification in drug-induced bullouspemphigoid. J Am Acad Dermatol 1993;29(5Pt 2):879-82.
Lee JJ, Downham TF 2nd. Furosemide-induced bullous pemphigoid: case report andreview of literature. J Drugs Dermatol 2006;5(6):562-4.
Wojnarowska F, Kirtschig G, Highet AS,et al. Guidelines for the management ofbullous pemphigoid. Br J Dermatol 2002;147(2):214-21.
Joly P, Roujeau JC, Benichou J, et al. Acomparison of oral and topical corticosteroidsin patients with bullous pemphigoid. N Engl JMed 2002;346(5):321-7.
Ahmed AR. Intravenous immunoglobulintherapy for patients with bullous pemphigoidunresponsive to conventionalimmunosuppressive treatment. J Am AcadDermatol 2001;45(6):825-35
Leonardi CL. Efalizumab: an overview. J AmAcad Dermatol 200349(2 Suppl):S98-104